385 related articles for article (PubMed ID: 26043662)
1. Effective virtual screening strategy focusing on the identification of novel Bruton's tyrosine kinase inhibitors.
Xiao J; Zhang S; Luo M; Zou Y; Zhang Y; Lai Y
J Mol Graph Model; 2015 Jul; 60():142-54. PubMed ID: 26043662
[TBL] [Abstract][Full Text] [Related]
2. Exploration of Novel Inhibitors for Bruton's Tyrosine Kinase by 3D QSAR Modeling and Molecular Dynamics Simulation.
Bavi R; Kumar R; Choi L; Woo Lee K
PLoS One; 2016; 11(1):e0147190. PubMed ID: 26784025
[TBL] [Abstract][Full Text] [Related]
3. Pharmacophore modeling and virtual screening in search of novel Bruton's tyrosine kinase inhibitors.
Sharma A; Thelma BK
J Mol Model; 2019 Jun; 25(7):179. PubMed ID: 31172362
[TBL] [Abstract][Full Text] [Related]
4. Discovery of novel Bruton's tyrosine kinase inhibitors using a hybrid protocol of virtual screening approaches based on SVM model, pharmacophore and molecular docking.
Wan HL; Wang ZR; Li LL; Cheng C; Ji P; Liu JJ; Zhang H; Zou J; Yang SY
Chem Biol Drug Des; 2012 Sep; 80(3):366-73. PubMed ID: 22594639
[TBL] [Abstract][Full Text] [Related]
5. QSAR analysis of nicotinamidic compounds and design of potential Bruton's tyrosine kinase (Btk) inhibitors.
Santos-Garcia L; Assis LC; Silva DR; Ramalho TC; da Cunha EF
J Biomol Struct Dyn; 2016 Jul; 34(7):1421-40. PubMed ID: 26305710
[TBL] [Abstract][Full Text] [Related]
6. Combined pharmacophore, virtual screening and molecular dynamics studies to identify Bruton's tyrosine kinase inhibitors.
Sakthivel S; Habeeb SKM
J Biomol Struct Dyn; 2018 Dec; 36(16):4320-4337. PubMed ID: 29293382
[TBL] [Abstract][Full Text] [Related]
7. Pharmacophore modeling, multiple docking, and molecular dynamics studies on Wee1 kinase inhibitors.
Hu Y; Zhou L; Zhu X; Dai D; Bao Y; Qiu Y
J Biomol Struct Dyn; 2019 Jul; 37(10):2703-2715. PubMed ID: 30052133
[TBL] [Abstract][Full Text] [Related]
8. Molecular modeling studies on series of Btk inhibitors using docking, structure-based 3D-QSAR and molecular dynamics simulation: a combined approach.
Balasubramanian PK; Balupuri A; Cho SJ
Arch Pharm Res; 2016 Mar; 39(3):328-39. PubMed ID: 26699616
[TBL] [Abstract][Full Text] [Related]
9. Identification of novel PI3Kδ inhibitors by docking, ADMET prediction and molecular dynamics simulations.
Liu YY; Feng XY; Jia WQ; Jing Z; Xu WR; Cheng XC
Comput Biol Chem; 2019 Feb; 78():190-204. PubMed ID: 30557817
[TBL] [Abstract][Full Text] [Related]
10. Discovery of Potent Bruton's Tyrosine Kinase Inhibitors Using Ligand Based Modeling.
Mera WA; Alzihlif M; Taha MO; Khanfar MA
Anticancer Agents Med Chem; 2017; 17(2):265-275. PubMed ID: 27671297
[TBL] [Abstract][Full Text] [Related]
11. Ligand- and structure-based in silico studies to identify kinesin spindle protein (KSP) inhibitors as potential anticancer agents.
Balakumar C; Ramesh M; Tham CL; Khathi SP; Kozielski F; Srinivasulu C; Hampannavar GA; Sayyad N; Soliman ME; Karpoormath R
J Biomol Struct Dyn; 2018 Nov; 36(14):3687-3704. PubMed ID: 29064326
[TBL] [Abstract][Full Text] [Related]
12. TR-FRET binding assay targeting unactivated form of Bruton's tyrosine kinase.
Asami T; Kawahata W; Sawa M
Bioorg Med Chem Lett; 2015; 25(10):2033-6. PubMed ID: 25872980
[TBL] [Abstract][Full Text] [Related]
13. Identification of non-resistant ROS-1 inhibitors using structure based pharmacophore analysis.
Pathak D; Chadha N; Silakari O
J Mol Graph Model; 2016 Nov; 70():85-93. PubMed ID: 27693947
[TBL] [Abstract][Full Text] [Related]
14. The development of Bruton's tyrosine kinase (BTK) inhibitors from 2012 to 2017: A mini-review.
Liang C; Tian D; Ren X; Ding S; Jia M; Xin M; Thareja S
Eur J Med Chem; 2018 May; 151():315-326. PubMed ID: 29631132
[TBL] [Abstract][Full Text] [Related]
15. Pharmacophore modeling study based on known spleen tyrosine kinase inhibitors together with virtual screening for identifying novel inhibitors.
Xie HZ; Li LL; Ren JX; Zou J; Yang L; Wei YQ; Yang SY
Bioorg Med Chem Lett; 2009 Apr; 19(7):1944-9. PubMed ID: 19254842
[TBL] [Abstract][Full Text] [Related]
16. Bayesian machine learning to discover Bruton's tyrosine kinase inhibitors.
Wang J; Ran T; Chen Y; Lu T
Chem Biol Drug Des; 2020 Oct; 96(4):1114-1122. PubMed ID: 31855311
[TBL] [Abstract][Full Text] [Related]
17. Virtual screening and structure-activity relationship study of novel BTK inhibitors in Traditional Chinese Medicine for the treatment of rheumatoid arthritis.
Sun L; Wang Z; Yang Z; Liu X; Dong H
J Biomol Struct Dyn; 2023; 41(24):15219-15233. PubMed ID: 36914235
[TBL] [Abstract][Full Text] [Related]
18. Novel virtual lead identification in the discovery of hematopoietic cell kinase (HCK) inhibitors: application of 3D QSAR and molecular dynamics simulation.
Bavi R; Kumar R; Rampogu S; Kim Y; Kwon YJ; Park SJ; Lee KW
J Recept Signal Transduct Res; 2017 Jun; 37(3):224-238. PubMed ID: 27485399
[TBL] [Abstract][Full Text] [Related]
19. Discovery of novel Bruton's tyrosine kinase (BTK) inhibitors bearing a pyrrolo[2,3-d]pyrimidine scaffold.
Zhao X; Huang W; Wang Y; Xin M; Jin Q; Cai J; Tang F; Zhao Y; Xiang H
Bioorg Med Chem; 2015 Feb; 23(4):891-901. PubMed ID: 25596757
[TBL] [Abstract][Full Text] [Related]
20. Exploration of potential EGFR inhibitors: a combination of pharmacophore-based virtual screening, atom-based 3D-QSAR and molecular docking analysis.
Sudha A; Srinivasan P; Rameshthangam P
J Recept Signal Transduct Res; 2015 Apr; 35(2):137-48. PubMed ID: 25069678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]